157 related articles for article (PubMed ID: 17548040)
21. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM
J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687
[No Abstract] [Full Text] [Related]
22. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
23. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
[TBL] [Abstract][Full Text] [Related]
24. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
Forrer F; Riedweg I; Maecke HR; Mueller-Brand J
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):334-40. PubMed ID: 18480742
[TBL] [Abstract][Full Text] [Related]
25. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
de Keizer B; van Aken MO; Feelders RA; de Herder WW; Kam BL; van Essen M; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):749-55. PubMed ID: 18210106
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
Breeman WA; Mearadji A; Capello A; Bernard BF; van Eijck CH; Krenning EP; de Jong M
Int J Cancer; 2003 Apr; 104(3):376-9. PubMed ID: 12569562
[TBL] [Abstract][Full Text] [Related]
27. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
28. Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a New
Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
[TBL] [Abstract][Full Text] [Related]
30. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
Teunissen JJ; Kwekkeboom DJ; de Jong M; Esser JP; Valkema R; Krenning EP
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):595-616. PubMed ID: 16183530
[TBL] [Abstract][Full Text] [Related]
31. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
Miao Y; Fisher DR; Quinn TP
Nucl Med Biol; 2006 Aug; 33(6):723-33. PubMed ID: 16934691
[TBL] [Abstract][Full Text] [Related]
32. The visualization of gastroenteropancreatic endocrine tumors.
Lamberts SW; Chayvialle JA; Krenning EP
Metabolism; 1992 Sep; 41(9 Suppl 2):111-5. PubMed ID: 1355584
[TBL] [Abstract][Full Text] [Related]
33. Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats.
Laznicek M; Laznickova A; Mäcke HR; Eisenwiener K; Reubi JC; Wenger S
Cancer Biother Radiopharm; 2002 Oct; 17(5):527-33. PubMed ID: 12470422
[TBL] [Abstract][Full Text] [Related]
34. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.
Teunissen JJ; Kwekkeboom DJ; Krenning EP
Trends Endocrinol Metab; 2006; 17(1):19-25. PubMed ID: 16311041
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours.
Capurso G; Panzuto F; Delle Fave G
Dig Liver Dis; 2010 Mar; 42(3):173-4. PubMed ID: 20117969
[No Abstract] [Full Text] [Related]
36. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP
J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990
[TBL] [Abstract][Full Text] [Related]
37. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
Villard L; Romer A; Marincek N; Brunner P; Koller MT; Schindler C; Ng QK; Mäcke HR; Müller-Brand J; Rochlitz C; Briel M; Walter MA
J Clin Oncol; 2012 Apr; 30(10):1100-6. PubMed ID: 22393097
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
[TBL] [Abstract][Full Text] [Related]
39. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
Fehmann HC; Wulbrand U; Arnold R
Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
[TBL] [Abstract][Full Text] [Related]
40. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
